Figure 2
Rhodocytin-induced plasma extravasation in the skin requires mast cells and histamine. (a) Representative images of C48/80 (10 μg/20 μl i.d.)- or rhodocytin (5 μmol/L/20 μl i.d.)-induced plasma extravasation in wild-type mice, mast cell–deficient W/Wv mice, or mast cell–deficient W/Wv mice reconstituted with subcutaneous injections of wild-type BMMCs (color), and digitized images used for density value evaluations (black and white) (upper panels). Quantitative analysis of the images in the upper panels (lower panel). Values represent means ± SD. One-way ANOVA with Bonferroni’s test: *p < 0.05, **p < 0.01 (n = 5). (b) Plasma samples were collected 10 minutes after i.d. injection of wild-type mice with C48/80 (10 μg/40 μl) or rhodocytin (5 μmol/L/40 μl). Blood levels of histamine were measured with the histamine EIA kit. Values represent means ± SD. One-way ANOVA with Bonferroni’s test: *p < 0.05, **p < 0.01 (n = 5). (c) Representative images of C48/80 (10 μg/20 μl i.d.)- or rhodocytin (5 μmol/L/20 μl i.d.)-induced plasma extravasation in wild-type mice pretreated with or without the histamine H1 receptor antagonist olopatadine (10 mg/kg p.o.), and digitized images used for density value evaluations (upper panels). Quantitative analysis of the images in the upper panels (lower panel). Values represent means ± SD. One-way ANOVA with Bonferroni’s test: *p < 0.05, **p < 0.01 (n = 5). (d) Representative images of PAF (10 μmol/L/20 μl i.d.)- or rhodocytin (5 μmol/L/20 μl i.d.)-induced plasma extravasation in wild-type mice pretreated with or without the PAF receptor antagonist WEB2086 (10 mg/kg i.v.) or ABT491 (10 mg/kg i.v.), and digitized images used for density value evaluations (upper panels). Quantitative analysis of the images in the upper panels (lower panel). Values represent means ± SD. One-way ANOVA with Bonferroni’s test: *p < 0.05, **p < 0.01 (n = 5). (a–d) Similar results were obtained from at least two independent experiments.
